The proangiogenic biomarker, placental growth factor (PlGF), and the antiangiogenic biomarker, soluble vascular endothelial growth factor receptor-1 (sFlt-1), both mainly derived from the placental trophoblast, seem to accurately diagnose and predict early onset preeclampsia (delivery ≤ 34 WOG) (7) or even preterm PE (PE ≤ 37 WOG) as well as fetal and neonatal adverse outcomes (8) and might improve the allocation of care (9, 10). This evidence concerns the gene FLT1 and preeclampsia.